ORIC Pharmaceuticals (ORIC) Earnings Analysis
ORIC Pharmaceuticals (ORIC) next reports earnings on 2026-08-11, consensus EPS -0.36 USD. Last quarter (2026-05-04) it missed with EPS -0.34 USD vs -0.32075 USD est (-6%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -7.47.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ORIC next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.36 USD |
| Revenue estimate | n/a |
ORIC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-04 | -0.34 USD | -0.32075 USD | -6% | Miss |
| 2026-02-23 | -0.3 USD | -0.34 USD | +11.8% | Beat |
| 2025-11-13 | -0.33 USD | -0.41 USD | +19.5% | Beat |
| 2025-05-05 | -0.42 USD | -0.51 USD | +17.6% | Beat |
| 2025-02-18 | -0.51 USD | -0.52 USD | +1.9% | Beat |
| 2024-08-12 | -0.45 USD | -0.42 USD | -7.1% | Miss |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
ORIC valuation and analyst view
| Trailing P/E | -7.47 |
|---|---|
| Trailing EPS | -1.28198 USD |
| Price / book | 2.73 |
| Dividend yield | 0.00% |
| Market cap | 1.09B |
| Analyst consensus | Buy (10 buy / 0 hold / 0 sell) |
| Avg price target | 15 USD |
Related research pages
Frequently asked questions
When is ORIC Pharmaceuticals (ORIC)'s next earnings date?
ORIC Pharmaceuticals is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.36 USD.
Did ORIC beat earnings last quarter?
In its 2026-05-04 report, ORIC posted EPS of -0.34 USD versus a -0.32075 USD estimate — a miss of 6%.
What is ORIC's earnings track record?
Over the last 6 reported quarters with consensus data, ORIC beat estimates 4 times (67%).
What is ORIC's current P/E ratio and EPS?
ORIC trades at a trailing P/E of -7.47 on trailing EPS of -1.281980222268941 USD.
What do analysts rate ORIC?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 15 USD.